MST Access analyst coverage
MST Access have released analyst coverage of Arovella with a valuation of A$0.34.
Key highlights:
Cutting-edge. Human trials start CY25. Undervalued.
CAR-iNKT is the next frontier in cancer immunotherapy
Potential to transform gains in CAR-T cell therapy for blood cancer to solid tumours, at lower cost & off-the-shelf therapy
ALA: next generation cutting-edge science within the ‘class’
CY25 - 1st human trial - key validation & valuation point
